pharma · Psoriasis Vulgaris · Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.
LEO Pharma US
LEO Pharma A/S
LEO Pharma US trial registry — 7 ClinicalTrials.gov studies with program phase, status, and indication context.
Madison, USA HQ
1908 Founded
75 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Madison, USA
- Founded
- 1908
- Employees
- 75
- Programs
- 7
- Drugs
- 11
- Patents
- 0
LEO Pharma US clinical trials
Registry index of 7 ClinicalTrials.gov studies linked to LEO Pharma US programs — each row shows trial ID, program name, phase, status, and indication.
LEO Pharma US trial registry — 7 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for LEO Pharma US.
-
LP0162-2328 — Approved
Clinical update -
LP0189-2318 — Phase 1
Clinical update -
LP0162-1336 — Phase 3
Clinical update -
LP0160-1329 — Approved
Clinical update -
Adtralza 150 mg solution for injection in pre-filled syringe — Phase 2
Clinical update -
LEO 90105 — Phase 2
Clinical update -
Delgocitinib cream, Cream Vehicle — Phase 2
Clinical update
Trial registry
-
CTIS ↗ -
CTIS ↗ -
CTIS ↗ -
CTIS ↗ - 2024-512791-36-00CTIS ↗
Adtralza 150 mg solution for injection in pre-filled syringe
Treatment of moderate-to-severe Atopic dermatitis
-
CTIS ↗ -
CT.gov ↗